OTC SPERMICIDE TRIALS EVALUATING STD PROTECTIVE BENEFITS
This article was originally published in The Tan Sheet
Executive Summary
OTC SPERMICIDE TRIALS EVALUATING STD PROTECTIVE BENEFITS should look at four specific endpoints in their design: human immunodeficiency virus (HIV) seroconversion, herpes infection transmission, papilloma infection transmission, and hepatitis seroconversion, FDA Division of Antiviral Drug Products Director David Feigal, MD, told a National Institutes of Health workshop on contraceptive efficacy and sexually transmitted disease prevention on April 7.